Elisrasib

Overview

Elisrasib (D3S-001) is an orally active and selective inhibitor for KRAS . Elisrasib inhibits the proliferation of KRAS G12C mutant H358 and MIA-PA-CA-2. D3S-001 also inhibits the phosphorylation of cellular ERK1/2 . Elisrasib exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Ras | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-160023
• CAS No.: 2914919-85-8
• Molecular Formula: C32H35F6N7O3
• Molecular Weight: 679.66
• Purity: 99.68%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (3.68 mM); Clear solution
• Availability: In-stock

Source

Original product source